ziltivekimab   Click here for help

GtoPdb Ligand ID: 11552

Synonyms: COR-001 | COR001 | MEDI-5117 | MEDI5117 | ZILTI
Compound class: Antibody
Comment: Ziltivekimab (MEDI5117) is a humanized monoclonal antibody directed against the IL-6 ligand. It was developed to inhibit pro-inflammatory IL-6 signalling in conditions that are associated with systemic inflammation, including atherosclerosis, chronic kidney disease, and rheumatoid arthritis [2], and it has also been explored for anti-tumour activity [4]. The Fc domain of ziltivekimab has been engineered to extend its half-life (by increasing affinity for FcRn), to support once-monthly administration [1].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
No information available.
Summary of Clinical Use Click here for help
Ziltivekimab (MEDI5117) has been investigated in phase 1 trials of patients with rheumatoid arthritis, and has been progressed to hase 2 studies for conditions that are driven in part by chronic inflammation.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT03926117 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition Phase 2 Interventional Novo Nordisk A/S
NCT04626505 Trial to Evaluate Reduction in Inflammation in Patients With Advanced Chronic Renal Disease Utilizing Antibody Mediated IL-6 Inhibition in Japan. Phase 2 Interventional Novo Nordisk A/S
NCT03126318 A Study of Patients With Chronic Kidney Disease to Assess the Safety of a Single Dose of COR-001 Phase 1 Interventional University of Colorado, Denver
NCT01559103 Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients Phase 1 Interventional Novo Nordisk A/S
NCT02868229 Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of COR-001 Phase 1/Phase 2 Interventional Novo Nordisk A/S 3